Companies › GV20 Therapeutics
1 active drug program in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GV20-0251 | – | Phase 1 | Solid Tumor, Adult; Solid Tumor Cancer; Head and Neck Squamous Cell Carcinoma HNSCC; HCC - Hepatocellular Carcinoma | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05669430 | GV20-0251 | Phase 1 | Solid Tumor, Adult | Oncology | Dec 2026 |
| NCT07457281 | GV20-0251 | Phase 1 | Head and Neck Squamous Cell Carcinoma HNSCC | Oncology | Apr 2027 |
| NCT07106827 | GV20-0251 | Phase 1 | HCC - Hepatocellular Carcinoma | Oncology | Jun 2027 |
| NCT07070518 | GV20-0251 | Phase 1 | Solid Tumor Cancer | Oncology | Jul 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.